Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
171.06 USD   +0.46%
02/06Drug companies face huge drop in sales in 2023
RE
02/06Personalis and Moderna Sign New Agreement to Leverage NeXT Platform in Personalized mRNA Cancer Vaccine Clinical Trials
AQ
02/06Drug companies face COVID cliff in 2023 as sales set to plummet
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna Rejects China's Request To Transfer COVID-19 Vaccine Technology Amid Safety Woes

10/02/2022 | 11:37pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about MODERNA, INC.
02/06Drug companies face huge drop in sales in 2023
RE
02/06Personalis and Moderna Sign New Agreement to Leverage NeXT Platform in Personalized mRN..
AQ
02/06Drug companies face COVID cliff in 2023 as sales set to plummet
RE
02/03Insider Sell: Moderna
MT
02/03Moderna to Continue Using Personalis' Genomics Platform for Investigational Cancer Vacc..
MT
02/01Analysis-GSK gives few clues on plans to replenish medicine cabinet
RE
02/01GSK profit grows as aims for first-ever approved RSV vaccine
AN
01/31China mRNA vaccine development jumps into high gear
RE
01/31Factbox-What ending the U.S. COVID health emergency means for your pocket
RE
01/30Moderna's Wins Breakthrough Therapy Designation from US FDA for Investigational Syncyti..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 100 M - -
Net income 2022 8 733 M - -
Net cash 2022 12 352 M - -
P/E ratio 2022 8,00x
Yield 2022 -
Capitalization 65 718 M 65 718 M -
EV / Sales 2022 2,79x
EV / Sales 2023 6,47x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 171,06 $
Average target price 229,19 $
Spread / Average Target 34,0%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Paul Burton Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-5.21%65 414
LONZA GROUP AG22.89%44 540
IQVIA HOLDINGS INC.13.38%43 149
ALNYLAM PHARMACEUTICALS, INC.-1.80%27 576
SEAGEN INC.5.83%25 250
ICON PUBLIC LIMITED COMPANY22.39%19 410